Triphala Guggulu
Triphala Guggulu is a classical Ayurvedic guggulu, a resin-based preparation. Listed in Ayurvedic Formulary of India (AFI) Part I; monographed in Ayurvedic Pharmacopoeia of India (API); individual Triphala components listed in WHO selected medicinal plants monographs.
| Also known as | Triphala Guggulu, TriphalaGuggulu |
|---|---|
| Pharmacopoeia status | Listed in Ayurvedic Formulary of India (AFI) Part I; monographed in Ayurvedic Pharmacopoeia of India (API); individual Triphala components listed in WHO selected medicinal plants monographs |
Names and identification
| Language | Name |
|---|---|
| English | Triphala Guggulu |
Where is it described in the classical texts?
Sharangdhara Samhita (Madhyama Khanda, Chapter 7); also described in Sushruta Samhita and Ashtanga Hridayam
How does it work?
- Adipogenesis inhibition: Triphala polyphenols suppress the PI3K/Akt signaling pathway and downregulate PPARG and C/EBPalpha transcription factors, inhibiting fat cell differentiation and proliferation
- Lipid metabolism regulation: Guggulsterones act as FXR antagonists promoting bile acid synthesis and cholesterol excretion; Triphala components reduce LDL-C, total cholesterol, and triglycerides while increasing HDL
- Anti-inflammatory and antioxidant: Gallic acid, ellagic acid, and chebulagic acid from Triphala reduce IL-6, CRP, and MDA levels while enhancing SOD and adiponectin
- Gut microbiome modulation: Triphala promotes growth of beneficial bacteria (Bifidobacterium, Lactobacillus) while inhibiting pathogenic bacteria, improving metabolic function
- Neurotransmitter regulation: Animal studies show increased serotonin and dopamine levels, suggesting regulation of appetite and mood pathways relevant to obesity
Which traditional uses are supported by research?
- Anti-obesity effects validated through systematic review and meta-analysis (2025) and molecular mechanism studies confirming PI3K/Akt pathway modulation
- Lipid-lowering activity validated in multiple RCTs showing reduction in LDL-C, total cholesterol, and triglycerides in treated groups
- Digestive regulation and Ama elimination validated through prebiotic effects on gut microbiome and laxative action
- Metabolic syndrome management supported by demonstrated effects on glucose, leptin, adiponectin, and inflammatory markers in animal models
What do recent clinical trials show?
- Inpan R, Sakuludomkan C, Na Takuathung M and others 2024. Network Pharmacology Revealing the Therapeutic Potential of Bioactive Components of Triphala and Their Molecular Mechanisms against Obesity. International journal of molecular sciences. PMID 39409084 · doi:10.3390/ijms251910755
Triphala bioactive compounds show strong binding affinity to AKT1 and PPARG receptors central to insulin signaling, lipid metabolism, and inflammation; suppression of PI3K/Akt pathway may inhibit adipogenesis. - Donato F, Raffetti E, Toninelli G and others 2021. Guggulu and Triphala for the Treatment of Hypercholesterolaemia: A Placebo-Controlled, Double-Blind, Randomised Trial. Complementary medicine research. PMID 33242870 · doi:10.1159/000510985
Three months of treatment did not show statistically superior effects versus placebo on total and LDL cholesterol, BMI, and waist circumference, indicating need for longer treatment duration or higher doses.
2 further claims previously listed here could not be traced to a published paper and have been removed. Classical formulations are researched largely in journals that PubMed does not index, so an absence here reflects the reach of the index rather than the state of the evidence.
Recent safety updates
- No serious adverse events reported across clinical trials; mild GI symptoms (loose stools) may occur due to laxative effect of Triphala; avoid in pregnancy, lactation, and severe dehydration
- Large well-designed RCTs still required to confirm long-term efficacy and safety; guggulu component may interact with anticoagulant and thyroid medications; discontinue 2 weeks before surgery
What is it made of?
Key Active Markers
- Derived from constituent herbs (see individual herb profiles)
- Standardized on primary bioactive markers
Analytical Methods: HPLC fingerprinting, TLC (identity), LC-MS/MS (marker quantification)
Dosage forms and preparation
Dosage Forms: Vati (pill/tablet), Capsule
Standard Dosage: 2 tablets twice daily
Bioavailability: Guggulu resin acts as natural bioenhancer; guggulsterones have moderate oral bioavailability (~40%); lipophilic matrix aids absorption of co-formulated herbs
Optimal Timing: After meals, twice daily
Shelf Life: 2 years (guggulu preparations per ASU); potency may decrease after 1 year
Storage: Airtight container, cool dry place; guggulu preparations are hygroscopic
Marker Compounds: Guggulsterone, Gallic acid, Piperine
Quality Parameters: Weight variation ±5%, disintegration <60 min, hardness 4-8 kP, assay: Guggulsterone, Gallic acid, Piperine, guggulsterone content
Vehicle (Anupana): Warm water
Synergistic Combinations
- Key herbs: Triphala, Guggulu, Pippali; guggulu potentiates anti-inflammatory and hypolipidemic actions
Composition
As given in the Ayurvedic Formulary of India, Part I, entry 5:5 (TRIPHALA GUGGULU), which cites Sarmgadharasamhita Madhyamakhanda Adhyaya 7;82-82½) — as OCR'd: "(Sarmgadharasamhita Madhyamakhanda Adhyaya 7;82-82%)". Names, parts and quantities are transcribed as printed and checked row by row against the book. Manufacturers' versions of a classical formulation can differ from the formulary.
| # | Ingredient | Part | Quantity |
|---|---|---|---|
| 1 | Haritaki | pericarp | 48 g. |
| 2 | Bibhitaka | pericarp | 48 g. |
| 3 | Amalaki * | pericarp | 48 g. |
| 4 | Krsna (pippali) (pippali (printed in the entry itself as "Krsna(pippali)")) * | pericarp | 48 g. |
| 5 | Guggulu-suddha | exudate | 240 g. |
* The scanned text was damaged at this row and the name was read from the entry's own Sanskrit verse.
Published research
Literature indexed in PubMed that concerns this subject, grouped by study type. A paper appearing here is a record of what has been published, not evidence that the subject works, and laboratory or animal results do not transfer to people. Study titles link to PubMed so you can read the source rather than take our word.
Randomised controlled trials1
- 2021. Guggulu and Triphala for the Treatment of Hypercholesterolaemia: A Placebo-Controlled, Double-Blind, Randomised TrialComplementary medicine research. PMID 33242870 · doi:10.1159/000510985
Laboratory and animal studies1
- 2024. Network Pharmacology Revealing the Therapeutic Potential of Bioactive Components of Triphala and Their Molecular Mechanisms against ObesityInternational journal of molecular sciences. PMID 39409084 · doi:10.3390/ijms251910755
Consult a qualified vaidya before acting on anything here. Ayurvedic practice is prescribed to a person, not to a condition: the same dravya is given, withheld or substituted depending on your constitution, your agni, the season and what else you are already taking. A page cannot know any of that. Self-prescribing from a reference is how the wrong preparation, the wrong dose or the wrong anupana gets used.
Educational reference only. Nothing on this page is medical advice, a diagnosis, or a recommendation to take anything. Traditional uses and research findings are reported as published, not as claims about what any product does. If you take prescribed medication, raise any interaction with the prescriber rather than acting on a page. See our editorial standards.